Design, synthesis, and pharmacological evaluation of [1, 3] dioxolo-chromeno[2,3-b]pyridines as anti-seizure agents. 2023

Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
Department of Chemistry, School of Science, Gitam Deemed to be University, Hyderabad, TS, India.

An efficient one-pot three-component reaction for the synthesis of [1,3]dioxolo[4',5':6,7]chromeno[2,3-b]pyridines 4(a-i) has been developed. Synthesis was achieved by reacting sesamol (1), aromatic aldehydes 2(a-i), and 2-aminopropene-1,1,3-tricarbonitrile (3) in the presence of triethylamine at 100 °C under neat reaction condition. Simple operational procedure, broad substrate scope, column chromatography free separations, and high yield of products make it an efficient and largely acceptable synthetic strategy. Synthesized compounds 4(a-i) were further screened for preliminary anticonvulsant activity using MES and scPTZ tests. These analogs were also checked for neurotoxicity and hepatotoxicity. Selected active compounds have been then screened quantitatively to determine ED50 and TD50 values. Analog 4h was found effective in both preclinical seizure models with significant therapeutic/toxicity profile (4h: ED50 = 34.7 mg/kg, MES test; ED50 = 37.9 mg/kg, scPTZ test; TD50 = 308.7 mg/kg). Molecular dynamic simulation for 100 ns of compound 4h-complexed with GABAA receptor revealed good thermodynamic behavior and fairly stable interactions (4h, Docking score =  - 10.94). In conclusion, effective synthetic strategy, significant anticonvulsant activity with good toxicity profile and detailed molecular modeling studies led us to anticipate the emergence of these analogs as valid leads for the development of future effective neurotherapeutic agents.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011963 Receptors, GABA-A Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop. Benzodiazepine-Gaba Receptors,GABA-A Receptors,Receptors, Benzodiazepine,Receptors, Benzodiazepine-GABA,Receptors, Diazepam,Receptors, GABA-Benzodiazepine,Receptors, Muscimol,Benzodiazepine Receptor,Benzodiazepine Receptors,Benzodiazepine-GABA Receptor,Diazepam Receptor,Diazepam Receptors,GABA(A) Receptor,GABA-A Receptor,GABA-A Receptor alpha Subunit,GABA-A Receptor beta Subunit,GABA-A Receptor delta Subunit,GABA-A Receptor epsilon Subunit,GABA-A Receptor gamma Subunit,GABA-A Receptor rho Subunit,GABA-Benzodiazepine Receptor,GABA-Benzodiazepine Receptors,Muscimol Receptor,Muscimol Receptors,delta Subunit, GABA-A Receptor,epsilon Subunit, GABA-A Receptor,gamma-Aminobutyric Acid Subtype A Receptors,Benzodiazepine GABA Receptor,Benzodiazepine Gaba Receptors,GABA A Receptor,GABA A Receptor alpha Subunit,GABA A Receptor beta Subunit,GABA A Receptor delta Subunit,GABA A Receptor epsilon Subunit,GABA A Receptor gamma Subunit,GABA A Receptor rho Subunit,GABA A Receptors,GABA Benzodiazepine Receptor,GABA Benzodiazepine Receptors,Receptor, Benzodiazepine,Receptor, Benzodiazepine-GABA,Receptor, Diazepam,Receptor, GABA-A,Receptor, GABA-Benzodiazepine,Receptor, Muscimol,Receptors, Benzodiazepine GABA,Receptors, GABA A,Receptors, GABA Benzodiazepine,delta Subunit, GABA A Receptor,epsilon Subunit, GABA A Receptor,gamma Aminobutyric Acid Subtype A Receptors
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics

Related Publications

Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
June 2010, European journal of medicinal chemistry,
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
March 2013, Journal of medicinal chemistry,
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
December 2022, Molecules (Basel, Switzerland),
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
February 2018, Archiv der Pharmazie,
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
December 2012, European journal of medicinal chemistry,
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
February 2012, Bioorganic & medicinal chemistry,
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
June 2022, Molecules (Basel, Switzerland),
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
January 1990, Polish journal of pharmacology and pharmacy,
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
June 2019, Molecules (Basel, Switzerland),
Visarapu Malathi, and Nissi Sharon, and Pannala Padmaja, and Deepak Lokwani, and Saurabh Khadse, and Prashant Chaudhari, and Atul A Shirkhedkar, and Pedavenkatagari Narayana Reddy, and Vinod G Ugale
November 2007, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!